This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Smith & Nephew's TRUCLEAR System: A Gold Standard For Removal Of Intrauterine Polyps And Fibroids

Stocks in this article: HOLX SNN

ANDOVER, Mass., April 6, 2011 /PRNewswire/ -- Smith & Nephew's (NYSE: SNN; LSE: SN) Endoscopy Division today announced that its TRUCLEAR™ System, an operative hysteroscopy device for the removal of intrauterine polyps and fibroids, has surpassed the 30,000 procedure milestone.

The TRUCLEAR System is a first-of-its kind device that pairs the visualization capabilities of a hysteroscope with minimally invasive tissue removal capabilities, allowing a fast and thorough capture and removal of intrauterine polyps and fibroids; and provides healthcare practitioners in obstetrics, gynecology and reproductive health with a uniquely user-friendly technique.

It's widely believed that 3 out of 4 women in U.S. will have a fibroid at some point in their lifetime.  According to a Medtech Insight November, 2007 report, abnormal uterine bleeding caused by uterine fibroids and polyps affect more than 4 million women in the U.S.

"The TRUCLEAR System was designed to overcome the primary challenges with current treatments," said Mira Sahney, GM, Gynecology for Smith & Nephew Endoscopy.  "The system is optimized to thoroughly and efficiently remove tissue so that physicians are not required to make multiple, time-consuming insertions into the uterine cavity.  This helps to reduce the risk of damage, which may also help preserve the chances of a future pregnancy."

According to recently published research**, hysteroscopic polypectomy and myomectomy in women with infertility, and without other gynecological symptoms, is effective in achieving a better pregnancy rate with fewer reported complications.

The TRUCLEAR System is designed to cleanly remove tissue from the uterine cavity, leaving the hysteroscopic view unobscured and ultimately allows healthcare practitioners greater clarity to complete a given procedure.  Unlike other treatment options that use a high-frequency electric current, the TRUCLEAR System uses a simple mechanical approach to remove fibroids and polyps.

"The TRUCLEAR System has quickly become the standard of care that women deserve," commented Robert M. Biter, M.D., founder, Seaside Women's Health, San Diego, Calif.  "It is a safe and effective way to diagnose and treat causes of abnormal uterine bleeding and risk of pregnancy loss.  TRUCLEAR has truly revolutionized my practice."

UPDATE: Patent Infringement Litigation against Hologic, Inc.

Smith & Nephew has a patent infringement lawsuit pending in the U.S. District Court in Massachusetts against Hologic ( Bedford, Mass.) (NasdaqGS: HOLX), claiming their MyoSure™ Tissue Removal System infringes a patent specifically used for the TRUCLEAR System and for minimally invasive treatment of intrauterine polyps and fibroids.  The lawsuit was initially filed against Interlace Medical ( Framingham, Mass.) which was subsequently acquired by Hologic in January, 2011.

Contact: Joe Metzger SVP, Corporate Communications Smith & Nephew Endoscopy (978) 749-1330 joe.metzger@smith-nephew.com

™Trademark of Smith & Nephew. Certain Marks Reg. U.S. Pat. & T.M. Off.

**Lieng M, Istre O, Qvigstad E. Treatment of endometrial polyps: a systematic review. Acta Obstet Gynecol Scand. 2010 Aug;89(8):992-1002; Bosteels J, Weyers S, Puttemans P, Panayotidis C, Van Herendael B, Gomel V, Mol BW, Mathieu C, D'Hooghe T. The effectiveness of hysteroscopy in improving pregnancy rates in subfertile women without other gynaecological symptoms: a systematic review. Hum Reprod Update. 2010 Jan-Feb;16(1):1-11

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs